Inspyr Therapeutics, Inc. Stock Other OTC
Equities
NSPX
US45782A4031
Biotechnology & Medical Research
Sales 2021 | - | Sales 2022 | - | Capitalization | 241K 330K |
---|---|---|---|---|---|
Net income 2021 | 2M 2.74M | Net income 2022 | -1M -1.37M | EV / Sales 2021 | - |
Net cash position 2021 | 197K 269K | Net Debt 2022 | 305K 417K | EV / Sales 2022 | - |
P/E ratio 2021 |
-0.4
x | P/E ratio 2022 |
-0.23
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 100% |
Managers | Title | Age | Since |
---|---|---|---|
Silvestre Raul
CEO | Chief Executive Officer | 53 | - |
Michael Elliott
CTO | Chief Tech/Sci/R&D Officer | - | 16-10-10 |
Members of the board | Title | Age | Since |
---|---|---|---|
Scott Ogilvie
BRD | Director/Board Member | 69 | 08-01-31 |
Silvestre Raul
CEO | Chief Executive Officer | 53 | - |
Claire Thomas
BRD | Director/Board Member | 68 | 16-10-11 |
1st Jan change | Capi. | |
---|---|---|
+5.66% | 111B | |
+11.23% | 105B | |
-0.38% | 21.93B | |
-12.15% | 22.34B | |
-7.66% | 18.59B | |
-36.52% | 18.12B | |
-10.09% | 16.96B | |
+3.33% | 13.7B | |
+36.58% | 12.45B |